2-(4-氨基-2-氯苯基)乙酸乙酯 | 50712-59-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-氨基-2-氯苯基)乙酸乙酯
• 英文名称: ethyl 2-(4-amino-2-chlorophenyl)acetate
• 英文别名: (4-Amino-2-chlorphenyl)essigsaeureethylester；(4-amino-2-chloro-phenyl)-acetic acid ethyl ester
• CAS: 50712-59-9
• 化学式: C₁₀H₁₂ClNO₂
• 分子量: 213.664
• InChiKey: FEHGDBZUKAEGSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,4-bis(ethyloxy)-2,3-naphthalenedicarboxylic acid 、 2-(4-氨基-2-氯苯基)乙酸乙酯 在 溶剂黄146 作用下， 生成
  参考文献：
  名称：

  Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP4 receptor partial agonist for the treatment of pain

  摘要：

  A novel series of EP4 agonists and antagonists have been identified, and then used to validate their potential in the treatment of inflammatory pain. This paper describes these novel ligands and their activity within a number of pre-chmcal models of pain, ultimately leading to the identification of the EP4 partial agonist GSK726701A. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2018.03.091
• 作为产物：
  描述：

  diethyl 2-(2-chloro-4-nitrophenyl)malonate 在 5% Pd(II)/C(eggshell) 氢气 作用下， 以 甲醇 为溶剂， 生成 2-(4-氨基-2-氯苯基)乙酸乙酯
  参考文献：
  名称：

  [EN] IMIDAZOLE DERIVATIVES AS IDO INHIBITORS
  [FR] DÉRIVÉS IMIDAZOLE COMME INHIBITEURS DE L'IDO

  摘要：

  目前提供的是通用结构式（VII）、（VIII）所示的IDO抑制剂及其药物组合物，用于调节色胺酸2,3-二氧化酶的活性；治疗色胺酸2,3-二氧化酶（IDO）介导的免疫抑制；治疗受益于色胺酸-2,3-二氧化酶酶活性抑制的医疗状况；增强包括给予抗癌药物在内的抗癌治疗的有效性；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染性疾病相关的免疫抑制。

  公开号：

  WO2011056652A1

文献信息

• Phenylacetamides Suitable as Protein Kinase Inhibitors
  申请人：Bold Guido

  公开号：US20080319005A1

  公开（公告）日：2008-12-25

  The invention relates to compounds of the formula (I) wherein the moieties R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, and salts thereof, as well as their use, methods of use for them and method of their synthesis, and the like. The compounds are protein kinase inhibitors and can, inter alia, be used in the treatment of various proliferative diseases.

  本发明涉及公式(I)的化合物，其中基团R1、R2、R3、R9、R10和Q以及X、Y和Z的定义如规范中所述，以及其盐，以及它们的使用、使用方法和合成方法等。这些化合物是蛋白激酶抑制剂，可以用于治疗各种增生性疾病。
• Phenylacetamides being FLT3 Inhibitors
  申请人：Furet Pascal

  公开号：US20100075980A1

  公开（公告）日：2010-03-25

  Compounds of formula wherein the residues R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, salts thereof; their use, methods of their use, processes for their production, pharmaceutical compositions comprising them, their combinations with second drug substances and the use thereof and the like. The compounds are protein kinase inhibitors and can be used for the treatment of diseases mediated by protein kinase inhibitors, e.g. for the treatment of various proliferative diseases.

  该专利涉及公式中残基R1、R2、R3、R9、R10和Q以及X、Y和Z的化合物，其盐；它们的使用，使用方法，生产过程，包含它们的制药组合物，它们与第二药物物质的组合及其使用等。这些化合物是蛋白激酶抑制剂，可用于治疗由蛋白激酶抑制剂介导的疾病，例如用于治疗各种增殖性疾病。
• Modulators of Mitotic Kinases
  申请人：Kasibhatla Srinivas Rao

  公开号：US20100190787A1

  公开（公告）日：2010-07-29

  The invention relates to compounds of Formula (I), a prodrug, a polymorph, a tautomer, an enantiomer, a stereoisomer, a solvate, an N-oxide, or a pharmaceutically acceptable salt thereof: (formula should be inserted here) which have inhibitory effect on one or more protein kinases that are involved in cell mitosis.

  本发明涉及式（I）的化合物，一种前药、多晶形、互变异构体、对映异构体、立体异构体、溶剂化物、N-氧化物或其药学上可接受的盐：（应在此处插入式）它们具有对参与细胞有丝分裂的一个或多个蛋白激酶具有抑制作用。
• Phenylacetamides being FLT3 inhibitors
  申请人：Novartis AG

  公开号：US07977338B2

  公开（公告）日：2011-07-12

  Compounds of formula wherein the residues R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, salts thereof; their use, methods of their use, processes for their production, pharmaceutical compositions comprising them, their combinations with second drug substances and the use thereof and the like. The compounds are protein kinase inhibitors and can be used for the treatment of diseases mediated by protein kinase inhibitors, e.g. for the treatment of various proliferative diseases.

  该文本的翻译如下： 化合物的公式为其中残基R1、R2、R3、R9、R10和Q以及X、Y和Z的定义如规范中所述，它们的盐；它们的使用、使用方法、生产过程、包含它们的药物组合物、它们与第二药物物质的组合以及它们的使用等。这些化合物是蛋白激酶抑制剂，可用于治疗通过蛋白激酶抑制剂介导的疾病，例如用于治疗各种增殖性疾病。
• Imidazole Derivatives as IDO Inhibitors
  申请人：Mautino Mario R.

  公开号：US20120277217A1

  公开（公告）日：2012-11-01

  Presently provided are IDO inhibitors of general formulae (VII), (VIII) as shown below and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

  目前提供的是通式（VII），（VIII）所示的IDO抑制剂及其制药组合物，用于调节吲哚胺2,3-二氧化酶的活性；治疗由吲哚胺2,3-二氧化酶（IDO）介导的免疫抑制；治疗受益于抑制吲哚胺2,3-二氧化酶酶活性的医疗状况；增强包括给予抗癌药物在内的抗癌治疗的有效性；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染病相关的免疫抑制。